

Antibody Engineering & Therapeutics Europe

05-07 June, 2018
Hilton Amsterdam
Amsterdam, The Netherlands



BRINGING YOU THE LATEST SCIENCE, TECHNOLOGIES AND PARTNERS NEEDED TO ACCELERATE NEXT GENERATION ANTIBODIES TOWARDS COMMERCIAL SUCCESS

Keynote Speakers to Help You Fast-Track Your Antibody Development



**Frontiers of
Immunotherapy**

Clive Wood, Ph.D.
Corporate Senior Vice President,
Global Head of Discovery Research,
BOEHRINGER INGELHEIM, *Germany*



**T cell Recognition
in Human Cancer**

Ton Schumacher, Ph.D.
Professor of Immunotechnology,
LEIDEN UNIVERSITY and
Principal Investigator,
THE NETHERLANDS CANCER
INSTITUTE, *The Netherlands*



**How Antibodies
Trigger Cytotoxicity?**

Prof. Paul W.H.I. Parren, Ph.D.
Professor, Department of
Immunohematology and Blood
Transfusion, LEIDEN UNIVERSITY
MEDICAL CENTER AND SPARRING
BIOLOGICS B.V., *The Netherlands*

Featured Presentations



**Immunomodulatory Target
Discovery Using Antibody
Technologies**

Katarina Radošević, Ph.D.
Global Head Biologics Research, SANOFI R&D, *France*



**Tools for Looking at Individual
Antibodies and Antibody/Antigen
Interactions including Novel
Methods for Modelling Antibodies**

Charlotte Deane, Ph.D.
Professor of Structural Bioinformatics & Head of Department,
DEPARTMENT OF STATISTICS UNIVERSITY OF OXFORD, *United Kingdom*

Produced by the Organizers of the Antibody Engineering & Therapeutics San Diego Event

Register Online by 15 December and Save Up to £400

AntibodyEngEU.com



SCIENCE

Accelerate your pipeline of antibody and protein therapeutics to market by applying best practices and lessons learned from case studies and new data presentations from global industry leaders working across the entire spectrum of antibody discovery and development.



TECHNOLOGY

Bring your product to market by meeting leading product and service providers showcasing exciting antibody technologies in our poster and exhibit hall.



NETWORKING

Connect with industry and academic scientists and executives from Europe and around the world focused on antibody and protein therapeutic discovery and development during luncheons, cocktail receptions and networking breaks. Networking has never been easier with the included conference app that allows you to view the attendee list and schedule meetings before, during and after the event.

PRELIMINARY AGENDA (as of December 6, 2017)

Pre-Conference Workshops* • Tuesday, 05 June, 2018

Morning Half-Day Workshop • 08:30-12:30

Workshop A: The Nuts and Bolts of Antibodies

Workshop Moderator:

Mahendra Deonarain, Ph.D., Chief Science & Operating Officer, Antikor Biopharma Ltd., *United Kingdom*

Afternoon Half-Day Workshop • 13:30-17:30

Workshop B: CAR-T & anti-CD3-based Bispecifics

Workshop Moderators:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

David Gilham, Ph.D., Vice President of Research & Development, Celyad S.A., *Belgium*

*Additional registration fee applies. See the pricing page or visit the website for more details.

MAIN CONFERENCE

Wednesday-Thursday, 06-07 June, 2018

Keynotes Speakers

Frontiers of Immunotherapy

Clive R. Wood, Ph.D., Corporate Senior Vice President, Global Head of Discovery Research, Boehringer Ingelheim, *Germany*

T cell Recognition in Human Cancer

Ton N. Schumacher, Ph.D., Professor of Immunotechnology, Leiden University and Principal Investigator, The Netherlands Cancer Institute, *The Netherlands*

How Antibodies Trigger Cytotoxicity?

Prof. Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and Sparring Biologics B.V., *The Netherlands*

Bioinformatics/Repertoires

Session Co-Chairs:

Andrew Martin, D.Phil., Reader in Bioinformatics and Computational Biology, Institute of Structural and Molecular Biology, Division of Biosciences, University College London, *United Kingdom*

Gunilla Karlsson Hedestam, Ph.D., Professor, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, *Sweden*

Patterns of Molecular Convergence in Antibody Repertoires Predict Antigen Exposure and Specificity

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, *Switzerland*

Bioinformatics Approaches to the Antibody Drug-discovery Problem

Jiye Shi, Ph.D., Fellow & Senior Director, Head of Global CADD, UCB, *Belgium*

Use of Antibody Sequence Analysis Tools to Discover anti-TIGIT Antagonists

Aaron Sato, Ph.D., Chief Scientific Officer, LakePharma, *USA*

Structurally Mapping Next-generation Sequencing Repertoires of Antibodies to Aid In-silico Therapeutic Design

Charlotte Deane, Ph.D., Professor of Structural Bioinformatics & Head of Department, Department of Statistics University of Oxford, *United Kingdom*

Intractable Targets/Antibody Discovery Technologies

Session Chair:

John McCafferty, Ph.D., Founder and CEO, IONTAS, *United Kingdom*

Immunomodulatory Target Discovery Using Antibody Technologies

Katarina Radošević, Ph.D., Global Head Biologics Research, Sanofi R&D, *France*

Encapsulation of Single Cells for Antibody Discovery

Andrew Griffiths, Ph.D., Professor of Biochemistry, École Supérieure de Chimie Industrielles de Paris (ESPCI), *France*

How Big Are Antibody Libraries Really? How Do We Improve Them? Are We Accessing the Full Diversity?

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, *USA*

Opportunities for Therapeutic Antibodies Directed at G Protein-coupled Receptors and Ion Channels

Cath Hutchings, Ph.D., Independent Consultant, *United Kingdom*

Generation of Ion Channel Blocking Antibodies by Fusing Venom-derived "Knottins" into Antibody CDR Loops

Aneesh Karatt-Vellatt, Ph.D., Senior Research Scientist, Iontas, *United Kingdom*

Antibody Effector Functions and Novel Formats

Session Co-Chairs:

Matthias Peipp, Ph.D., Professor and Head of Research, Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University Kiel, *Germany*

Jeanette Leusen, Ph.D., Associate Professor, Head Immunotherapy Group and UMAB Facility, Laboratory for Translational Immunology, UMC Utrecht, *The Netherlands*

Understanding Complement Pathways in Immune Defense

Piet Gros, Ph.D., Professor, Chemistry and Biomolecular Sciences, Utrecht University, *The Netherlands*

Anti-complement Antibodies

Peter Boross, Senior Scientist, Prothix, *The Netherlands*

A Novel Method to Induce DR5 Agonist Activity

Marije Overdijk, Scientist, Genmab BV, *The Netherlands*

A Novel FAP-targeted 4-1BB Agonist for Combination Immunotherapy

Christian Klein, Head Oncology Programs & Department Head Cancer Immunotherapy Discovery, Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, *Switzerland*

Fc Engineering to Enhance Immunostimulatory Antibodies for Cancer Therapy

Stephen A. Beers, Ph.D., Associate Professor in Cancer Immunology and Immunotherapy, Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton, *United Kingdom*

Targeting Immune Regulation at the Tumor Site: Defining the Interplay between Therapy and Tumor Microenvironment

Sergio A. Quezada, Ph.D., Professorial Research Fellow, Immune Regulation and Tumor Immunotherapy Group, UCL Cancer Institute, *United Kingdom*

PRELIMINARY AGENDA (as of December 4, 2017)

New Antibody Therapeutics in Inflammatory & Infectious Diseases

Session Chair:

Marie Kosco-Vilbois, Ph.D., Chief Scientific Officer, NovImmune SA, *Switzerland*

Overcoming the Challenges of Developing Therapeutics to Treat Autoimmune Disease

Yong-Jun Liu, M.D., Ph.D., Global Head of Research, R&D, Sanofi, *USA*

Using a Bispecific Format, KI Bodies for Non-oncology Therapeutic Development

Nicolas Fischer, Ph.D., Head of Research, Novimmune, *Switzerland*

Alternative Inhaled Administration: ALX-0171 Is An Inhaled Anti-RSV Nanobody with Potential Breakthrough for the Treatment of RSV infections

Diane Van Hoorick, Ph.D., Senior Project Leader, Ablynx, *Belgium*

Antibodies Alternative Delivery/Vaccines

Session Co-Chairs:

Özlem Türeci, M.D., Chair of CI3 (Cluster of Individualized Immune-Intervention) and Head of Clinical & Scientific Advisors Board, BioNTech, *Germany*

Ferry Ossendorp, Ph.D., Professor in Synthetic Vaccine Biology, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, *The Netherlands*

A Tetanus-way of Boosting T cell Responses

Sara Mangsbo, Ph.D., Senior Associate Lecturer, Department of Pharmaceutical Biosciences, Uppsala University, *Sweden*

Building Artificial APC with Specific Mabs, Delivery into APCs, Cross Presentation

Bas van der Schoot, Ph.D. Candidate, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, *The Netherlands*

Antibody-mediated Antigen Delivery to Antigen Presenting Cells via Fc Receptors

Diana Dudziak, Ph.D., Professor of DC-Biology, Laboratory of Dendritic Cell Biology, University Hospital of Erlangen, *Germany*

Novel Antibody-based Therapeutics for Cancer & Immuno-oncology

Session Co-Chairs:

Agamemnon Epenetos, Ph.D., Consultant in Clinical Oncology, The Harley Street Clinic and Visiting Professor, Imperial College London, *United Kingdom*

Nicholas Wilson, Ph.D., Head of Immuno-Oncology, Gilead Sciences

Additional Confirmed Speakers

CAR-T Design Theory to Practice

Martin Pule, Ph.D., Senior Lecturer in Haematology, UCL Cancer Institute, University College London, *United Kingdom*

Fundamentals of Mass Spectrometry in the Analysis of Protein Therapeutics

Ewald Van den Bremer, Ph.D., Senior Scientist, Genmab, *The Netherlands*

Phage Display

John McCafferty, Ph.D., Founder and CEO, IONTAS, *United Kingdom*

IgA As a Novel Isotype for Treatment of Lymphoma and Neuroblastoma

Jeanette Leusen, Ph.D., Associate Professor, Head Immunotherapy Group and UMAB Facility, Laboratory for Translational Immunology, UMC Utrecht, *The Netherlands*

Fc-mediated Effector Function

Matthias Peipp, Ph.D., Professor and Head of Research, Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University Kiel, *Germany*

ADCs and Structure/Function/Stability

Mahendra Deonarain, Ph.D., Chief Science & Operating Officer, Antikor Biopharma Ltd., *United Kingdom*

Exploiting Natural Killer Specificity for CAR-T Cancer Therapy

David Gilham, Ph.D., Vice President of Research & Development, Celyad S.A., *Belgium*

SPONSORSHIP/EXHIBITION OPPORTUNITIES

Become a sponsor or exhibitor and connect face-to-face with 250+ highly influential scientists, engineers and executives from industry and academia with the budget and authority to recommend, specify and approve the purchase of products and services to accelerate antibody research, discovery efforts and clinical programs.

Showcase your products and services directly to this audience of antibody researchers and senior decision makers through:

- **Exhibit Booth Packages – only 8 left!**
- **Scientific Briefings – only 6 left!**
- **Custom Emails**
- **Branding touches – lanyards, conference totes, pad, pens, etc.**

A wide variety of options are available to help you meet your company objectives before, during and after the conference.

CONNECT WITH 250+ BUYERS – RESERVE YOUR EXHIBIT BOOTH OR SPONSORSHIP TODAY!

For more information on how you can connect with these key buyers, contact:

Aimee L. Croke, Business Development Manager, Life Sciences • T: +1-857-504-6697 • E: aimee.croke@knect365.com

Register Online by 15 December and Save Up to £400 - AntibodyEngEU.com

EXHIBITORS AND SPONSORS

(as of December 7, 2017)

Scientific Briefing Sponsor



Exhibitors

